IP Library Granted Patent US 11,345,898
Granted Patent B2
US 11,345,898 · App. 17/085,783 · Granted May 31, 2022

Ketoreductase polypeptides for the preparation of phenylephrine

Inventors: Oscar Alvizo (Fremont, CA); Steven J. Collier (Concord, MA); Hans-Georg Joerg Hennemann (Bedburg, DE); Seong Ho Oh (Singapore, SG); Wenjuan Zha (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/0006A61K31/137C12P13/001C12Y101/01184
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,345,898
App. No.
17/085,783
Granted
May 31, 2022
Kind
B2
Abstract

The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Claims (16)

1. An engineered polynucleotide encoding an engineered polypeptide capable of converting 1-(3-hydroxyphenyl)-2-(methylamino)ethanone to (R)-phenylephrine, wherein the amino acid sequence of the polypeptide has at least 95% identity to SEQ ID NO: 4 and comprises at least one residue difference selected from C190G, A202F, M206C, and Y249F.

2. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the at least one residue difference is M206C.

3. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence comprises at least two further residue differences selected from V95M, S96L, L147I, C190G, A202F, and Y202F.

4. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence comprises the residue differences: V95M, A202F, and M206C.

5. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence comprises the residue differences: V95M, C190G, A202F, and M206C.

6. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence comprises the residue differences: V95M, C190G, A202F, M206C, and Y249F.

7. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence comprises the combination of residue differences of any one of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34 as compared to SEQ ID NO: 2.

8. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the amino acid sequence further comprises at least one residue difference selected from T2S, I11L, A64V, T76I, V95M, S96L, V99L, V148L, T152A, L153M, S159T, D197A, and E200P.

9. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the polypeptide is capable of stereospecifically converting 1-(3-hydroxyphenyl)-2-(methylamino)ethanone to (R)-phenylephrine in a enantiomeric excess of at least 99%.

10. The engineered polynucleotide encoding an engineered polypeptide of claim 1 , wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34.

11. An expression vector comprising the engineered polynucleotide of claim 1 .

12. The expression vector of claim 11 , operably linked to a control sequence suitable for directing expression in a host cell.

13. A host cell comprising the expression vector of claim 11 .

14. A host cell comprising the expression vector of claim 12 .

15. A method for preparing an engineered polypeptide, comprising culturing a host cell of claim 13 , and optionally isolating the polypeptide from the cell.

16. A method for preparing an engineered polypeptide, comprising culturing a host cell of claim 14 , and optionally isolating the polypeptide from the cell.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (7)
Continuation 16778368 · Jan 31, 2020
Continuation 16437354 · Jun 11, 2019
Continuation 15812628 · Nov 14, 2017
Continuation 14755056 · Jun 30, 2015
Division 13390677
Provisional Application 61235324 · Aug 19, 2009
Related Publication 20210062162A1 · Mar 4, 2021
Cited By (1)
US 12,480,100